University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Alexander R. Gottschalk, MD, PhD

Alexander R. Gottschalk, MD, PhD

Assistant Professor, Department of Radiation Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Education

University of Chicago, Chicago, IL, B.A., 1988, Chemistry
University of Chicago, Chicago, IL, Ph.D., 1994, Pathology
University of Chicago, Chicago, IL, M.D., 1996, Medicine
Kaiser Permanente Medical Center, 1996-1997, Internship Medicine
University of California, San Francisco, 1997-2001, Resident Radiation Oncology


Professional Experience

  • 2001-2008
    Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2007-2008
    Interim Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Associate Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1988-96
    NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
  • 1998-99
    NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
  • 2000
    RSNA Research and Education Foundation Roentgen Resident/Fellow Research Award
  • 2001-02
    Clinical Investigator Research Program Recipient, University of California San Francisco
  • 2002
    Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD,
  • 2002-03
    UCSF Prostate Cancer SPORE Developmental Research Program Award
  • 2003-05
    RSNA Research Scholar Award
  • 2003-05
    American Society of Therapeutic Radiation and Oncology Junior Faculty Award

Selected Publications

  1. Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M. Respiration-Induced Intraorgan Deformation of the Liver. Technol Cancer Res Treat. 2017 Jan 01; 1533034616687193.
    View on PubMed
  2. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276.
    View on PubMed
  3. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84.
    View on PubMed
  4. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One. 2016; 11(10):e0164558.
    View on PubMed
  5. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847.
    View on PubMed
  6. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e109-e116.
    View on PubMed
  7. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat. 2017 Apr; 16(2):178-187.
    View on PubMed
  8. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72.
    View on PubMed
  9. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR. An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation. Technol Cancer Res Treat. 2017 Jun; 16(3):267-275.
    View on PubMed
  10. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8.
    View on PubMed
  11. McGuinness CM, Gottschalk AR, Lessard E, Nakamura JL, Pinnaduwage D, Pouliot J, Sims C, Descovich M. Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients. J Appl Clin Med Phys. 2015 Sep; 16(5):284-295.
    View on PubMed
  12. Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma. 2015; 2015:913565.
    View on PubMed
  13. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):795-800.
    View on PubMed
  14. Bomberg H, Albert N, Schmitt K, Gräber S, Kessler P, Steinfeldt T, Hering W, Gottschalk A, Standl T, Stork J, Meißner W, Teßmann R, Geiger P, Koch T, Spies CD, Volk T, Kubulus C. Obesity in regional anesthesia--a risk factor for peripheral catheter-related infections. Acta Anaesthesiol Scand. 2015 Sep; 59(8):1038-48.
    View on PubMed
  15. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  16. Descovich M, McGuinness C, Kannarunimit D, Chen J, Pinnaduwage D, Pouliot J, Kased N, Gottschalk AR, Yom SS. Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: insights from lung tumor patients treated with robotic radiosurgery. Med Phys. 2015 Mar; 42(3):1280-7.
    View on PubMed
  17. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
    View on PubMed
  18. Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy. Technol Cancer Res Treat. 2015 Feb; 14(1):49-60.
    View on PubMed
  19. Schnabel A, Middendorf B, Boschin MG, Gottschalk A, Van Aken H, Zahn PK, Pogatzki-Zahn EM. [Differences of analgesic efficacy and complication rates between ultrasound and nervestimulator guided peripheral nerve catheters : Database analysis on patient-relevant target parameters]. Anaesthesist. 2014 Nov; 63(11):825-31.
    View on PubMed
  20. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed

Go to UCSF Profiles, powered by CTSI